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PREFACE: 
My plan coming out of high school was to go into medicine and become a 
physician. Quickly, I learned that I also had a passion for research. As an 
undergraduate at UM-Flint, I was very fond of my research experiences even 
though 75 % of the time I felt like nothing worked. My professors saw early on in 
my career that I would make a promising scientist one day. To that end, my 
professors pushed for me to go to graduate school and obtain my Ph.D. For the 
past five years, I would go to an American Chemical Society (ACS) national 
meeting with my professors and they would have the "life conversion" with me, 
always steering me towards a Ph.D. career. I was stern on becoming a medical 
doctor; however, I did listen to them ... kind of! While a 3rd year undergraduate in 
the Honors Biochemistry program, I decided to complete another bachelor's 
degree in Molecular Biology and Biotechnology. Then in my 4th year, I decided on 
taking my professors' advice and went to graduate school at UM-Flint. I applied 
to the 2 year BS/MS Biochemistry program at UM-Flint still as an undergraduate 
completing a 2nd bachelors degree. At the time, the program was only accepting 
"in house" students and because of the passion for science I showed, I was 
accepted without a problem into the program. There were a lot of hurdles to 
overcome such as actually graduating from the program. Since its beginning, a 
handful of students have tried to complete the program but were unsuccessful. 
To date, I will be the first and only student to graduate from the program with a 
Masters in Biochemistry degree. Sadly, during my last year in the program I was 
told that the program would be stopped. So (for now) I will be the first and last 
Biochemistry student to graduate from the department. Completing my master's 
degree is not an end to my research career even though I will attend medical 
school in the fall. In fact, I know that my passions for research will continue from 
a clinical perspective in the future. 
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ABSTRACT: 
Glutathione (GSH), an important antioxidant, is essential for proper 
mammalian biochemical function. Its mechanism as an antioxidant involves the 
neutralization of reactive oxygen species (ROS) to less harmful compounds like 
water. ROS are neutralized using oxidation/reduction reactions, where 
glutathione reacts with a ROS forming oxidized glutathione (GSSG) and a neutral 
species, like water, in the process. GSSG is then reduced to GSH by glutathione 
reductase. Therefore, a proper in vivo concentration of GSH may determine a 
cell's ability to survive stressful conditions, such as the presence of drug 
compounds: benserazide, hydrogen peroxide, or buthionine sulfoximine (BSO). 
The research presented in this thesis shows that common cell culture 
techniques, such as media replacement and cell washing, causes cells to be 
more susceptible to these drugs. To analyze the effects of the drugs, IG50 curves 
were constructed with results from cell viability assays under three cell treatment 
conditions: no media replacement, media replacement, and two times wash with 
PBS followed by media replacement. These experiments were performed using 
two triple-negative breast cancer cell lines, MDA-MB-231 and MDA-MB-468. One 
suspected cause of increased susceptibility is loss of total GSH inside of the cells 
and to measure total GSH, a luminescent assay was used. However, we 
concluded from experimentation that an increase in cell susceptibility to drugs is 
not due to loss of GSH. Future research is needed to determine the cause. 
Finally, these results suggest that procedures used in in vitro cell culture studies 
can cause changes to the cell viability and that these results should urge 
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researchers to develop a more universal cell culture protocol that is comparable 
to in vivo conditions. 
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Scientist Joseph de Rey-Pailhade may have first described glutathione 
(GSH) in the late 1880's, but it was not until 1921 that the term "glutathione" was 
coined and the polypeptide rediscovered by British, Nobel Prize winner Sir 
Frederick Gowland Hopkins. (1-3) Hopkins spent many years characterizing this 
protein, which he described as a dipeptide, in the newly established and built 
biochemistry building at Cambridge (2-4). He determined that two forms of the 
proteins existed, the thiol-reduced form and a disulfide-oxidized form known as 
GSSG, which at the time was not characterized. Although Hopkin's is credited 
with this milestone discovery, his error in structure has not been forgotten. 
Another group of scientists characterized and published the protein as a 
tripeptide (5), where in turn Hopkins reiterated in another publication that the 
protein was indeed a dipeptide. (6) It was not until a novel crystallization 
technique of glutathione was developed and used by Hunter and Eagle that 
Hopkins realized he was wrong. (7) He published a final article in 1929 that 
detailed his mistake and suggested that glutathione is a tripeptide made up of 
glutamic acid, glycine, and cysteine; later glutathione was shown to have exactly 
that structure. (7) 
Later, in the early 1950's, Robert B. Johnston and Konrad Bloch were the 
first to describe the biosynthesis of glutathione with the help of enzymes, 
cofactors, and ATP hydrolysis. (1,8-9) Since that time, advancement in science 
and technology have allowed for a more in-depth characterization of the 
biosynthesis mechanism. The first reaction of the biosynthesis involves the 
amino acids, glutamate and cysteine, and the heterodimeric enzyme, y-
glutamylcysteine ligase (GCl). This rate-limiting step depends on ATP as an 
energy source and at least one of the subunits of GCl, catalytic subunit (GClC), 
to catalyze the reaction to produce y-glutamylcysteine. (10) It was established that 
the catalytic subunit's activity was inhibited by GSH, and in fact, the two subunits 
could reversibly disassociate when too much GSH was present. This feedback 
inhibition allows for regulation of the biosynthesis of GSH. (11) Furthermore, it has 
been found that oxidative stress, specifically reactive oxygen species (ROS), 
improves the re-formation of GCL. (12) The last step is catalyzed by GSH 
synthase, a non-GSH-inhibited homodimeric enzyme, by adding glycine to the C 
terminus of v-glutamylcysteine. (13) The resulting GSH structure is special 
because of its stability inside of the cell. The stability of the protein is due to the 
glutamate and cysteine residues not linking through the normal a-carboxyl group 
but through v-carboxyl group. This type of bond is hydrolyzed only by y-
glutamyltranspeptidase (GGT), which is normally found on the external surface of 
most cells. (14) Unsurprisingly, more then 90% of GSH is found within the cell 
either in the cytosol or mitochondria. (10) 
As previously mentioned, regulation is vitally important in the biosynthesis 
pathway, especially for the GCl and GSH synthase enzymes. Regulation of 
these enzymes is induced through many biological molecules such as hormones 
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(insulin, cortisone, etc.) as well as xenobiotics such as ROS. (10) GCl's 
heterodimeric structure is regulated at both catalytic (GClC) and modifier 
(GClM) subunits. Many researchers have shown that both subunits are 
transcriptionally regulated, specifically upregulated, through a series of unrelated 
pathways induced by both hormones and xenobiotics, such as several PI3K 
signaling pathways (Le. PI3K1Aktlp70S6K), MEK, and p38 MAPK causing the 
upregulation of GClC promoter activity. (15-17) In addition, posttranslational 
regulation of GClC occurs when it is phosphorylated by protein kinase A, protein 
kinase C, or calcium calmodulin kinase II, causing a down regulation in GSH 
synthesis (18). Xenobiotic-induced regulation of GClM also occurs both at the 
transcriptional and translational level. One example involves ~-naphthoflavone (~ 
- NF) binding Nrf2 transcription factor allowing for a higher affinity binding to the 
GClM promoter sequence, thereby causing up regulation of the gene. (19) 
Unfortunately when it comes to GSH synthase, little is known about how it is 
regulated. (10) However, researchers have shown that GSH synthase is not 
regulated by GSH and that both GClC and GSH synthase are needed for 
efficient production of GSH. (20) Finally, no posttranslational regulation of GSH 
synthase has been published to date. 
The biochemical functions of GSH are critical because both forms of 
glutathione (GSH and GSSG) function in many human biochemical processes, 
including cell proliferation, apoptosis, and redox cell signaling to maintain human 
homeostasis. Furthermore, very low and very high levels of GSH result in 
pathological symptoms resulting in human disease. In a 1995 study, researchers 
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showed that upon decrease of GSH through buthionine sulfoximine (8S0) 
treatment, cells would not continue through the cell cycle. (21) Furthermore, it was 
found that GSH is directly involved in transition from S phase to G2. (21) The 
researcher attributed this finding with DNA synthesis and its coupling with GSH 
and ribonucleotide reductase. Although the connection may not be clear, GSH is 
used to maintain thioredoxin, which is a coenzyme of ribonucleotide reductase 
needed to maintain proper function. (22) In fact, when GSH leaves the cell, 
apoptotic proteins are triggered due to the decrease in GSH levels. (23) 
Furthermore, as previously mentioned, both forms of GSH function in redox 
reactions. The GSH redox cycle involves oxidized GSSG being reduced to GSH 
while NADPH molecules from metabolic pathways such as pentose phosphate 
pathway are also oxidized for energy and protons. The enzyme that reduces 
GSSG back to 2 GSH molecules is glutathione reductase (GR). (23-24) From there 
GSH can be oxidized again for many other roles or be used in signaling where 
GSH binds to a thiol residue of a protein through a glutathionylation reaction. (25) 
Furthermore, because of the glutathionylation reaction, many signaling molecules 
containing cysteine residues are protected from oxidative damage. Upon 
deglutathionylation, a protein may continue its normal function. The role of GSH 
in protection from oxidative damage is the central theme of this thesis. 
One of glutathione's most important functions involves using sulfur 
chemistry to eliminate oxidative stress, specifically ROS, through its oxidation-
reduction cycle. The body produces many types of molecules that induce 
oxidative stress such as superoxide and hydrogen peroxide. (26) These molecules 
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are byproducts of many metabolic processes such as fatty acid oxidation and the 
breakdown of superoxide by superoxide dismutase, creating hydrogen peroxide. 
(27) The breakdown of hydrogen peroxide is then catalyzed by several enzymes 
such as catalase. However, one of the most important systems is that of 
glutathione and glutathione peroxidases (GPx), B of which (GPx1-B) have been 
discovered thus far. (28) Furthermore, these selenoproteins, abbreviated SecGPx, 
(selenocysteine, Sec, in the catalytic center), specifically the selenolate (-SeH) 
group, reacts with hydrogen peroxide to produce water and selenic acid (-SeOH), 
which is reduced back to -SeH by 2 GSH molecules, resulting in GSSG as 
shown in the reactions below. (28) 
GPx- SeOH + OH-
GPx- SeO-+ H + + GSH GPx- Se-SG + H20 
GPx- Se-SG + GSH GPx- Se-+ H + + GSSG 
The human body is constantly trying to balance equilibrium levels of hydrogen 
peroxide so that levels are not high enough to damage the cells. High levels 
cause cancer in some cases because the oxidative agents oxidize DNA, RNA, 
and other biological molecules needed for living. 
Because of GSH's importance in the body (in vivo), especially in cell 
viability and cell death, the question becomes how do we further test its role in 
vitro? Furthermore, is it proper scientific technique to use what we obtain in vitro 
to represent in vivo processes? How is GSH affected in common plating 
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techniques such as media replacement and washing of cells? Reiners showed 
that 2 of their cell lines showed a loss (40-90%) of GSH while passaging, but 
returned back to normal after 24 hours. (29) In another study, researchers showed 
that 500/0 of the GSH was depleted in cell isolation procedures. (30) Lee (2009) 
concluded that H9c2 cardiac myocytes experienced a decrease in GSH when 
cells had their media replaced, ultimately leading to increased cell death by 
increased susceptibility to oxidative stress such as ROS. (31) There has been very 
little research done on other cell lines to further solidify the need for a change in 
common global cell culture and cell plating techniques. More research is needed 
to push biotechnology companies to develop assays and systems that do not 
require the removal or wash of cells to better mimic in vivo conditions. This thesis 
quantifies the effects of common cell plating techniques on cell viability via GSH 
levels using two breast cancer cell lines, MDA-MB-231 and MDA-MB-468. The 
conclusions made in this thesis were the result of a 2-year research project. 
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Initial Growth and Maintenance of MDA-MB-231 and MDA-MB-468. Most cell 
culture techniques were done in a LabGard ES Class II, Type B2 Biological 
Safety Cabinet (NuAire: Plymouth, MN). All equipment and chemicals entering 
and exiting the cabinet were sterilized using 70% ethanol. All chemicals and 
equipment used in cell culture were either sterile or sterilized and kept sterile. All 
chemicals that were used in cell culture were either at room temperature or 
heated to 37°C in an Isotemp water bath (Fisher Scientific: Pittsburg, PA). Both 
breast cell lines were purchased from ATCC (Manassas, VA). The original stock 
cell lines were thawed, pelleted via centrifugation at 250 g, and the supernatant 
was then removed. The cells were resuspended with 1 mL of respective media 
and added separately to BioLite 75 cm3 vented cell culture flasks by Thermo 
Scientific (Waltham, MA) containing 30 mL of respective media and 1 mL of Heat 
Inactivated Fetal Bovine Serum (HI FBS), certified Performance Plus (Gibco: 
Carlsbad, CA). The MDA-MB-231 cell line was maintained using Gibco 1X 
minimum essential media + GlutaMAX-1 (MEM) with Earle's salts supplemented 
with 1.0 % Gibco 100X antimycotic-antibiotic, 1.0 % Gibco 100X (100 mM) 
sodium pyruvate, and 10 % HI FBS. The MDA-MB-468 cell line was maintained 
using Gibco 1X Dulbecco's Modified Eagle Medium (DMEM) + GlutaMAX-1 
(DMEM) with 4.5 gIL D-Glucose supplemented with 1.0 % Gibco 100X 
9 
antimycotic-antibiotic, 1.0 % Gibco 100X (100 mM) sodium pyruvate, and 10 0/0 
HI FBS. All media were then subjected to filtration via Nalgene Rapid-Flow 75mm 
Filter Unit (Thermo Scientific: Waltham, MA). All cells were grown in a Thermo 
Scientific Forma Steri-Cycle CO2 incubator at 37°C and 5.0 % CO2. After 24 
hours, the media was removed and replaced with 30 mL of respective media. 
The cells were then incubated for another 48 hours for confluent growth. 
Long Term Maintenance and Freezer Stocks. Using the initial growth, the 
media was removed using the vacuum pipette system. Then 10 mL of Thermo 
Scientific HyClone 1 X DPBS/Modified supplemented with calcium and 
magnesium was added to the flask. After 30-60 seconds the DPBS was removed 
using an electronic pipette and 3-5 mL of Gibco 0.25 % (1 X) trypsin-EDTA was 
added. After 30 seconds all of the trypsin was removed except for 1 mL. For the 
MDA-MB-231 cells, the trypsinization process was done at room temperature, 
while the MDA-MB-468 cells were incubated at 37°C for 5-7 min. Once the cells 
had detached, the cells were split with their respective media into new, labeled 
flasks. Each split constitutes a new passage (p). A split ratio was recorded based 
on the following: 6 mL of appropriate media was added to the flask containing 1 
mL trypsin, then 1 mL was taken out and added to the new flask thereby 
recording a 1:7 split. The cells were split every 3rd then 4th day (Monday and 
Thursday). Freezer stocks were made following a couple of growth passages. 
After media was added following trypsinization, the entire sample was added to a 
Falcon tube and counted using a Bright-Line hemocytometer with a volume of 0.1 
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mm3 (Hausser Scientific: Horsham, PA). The hemocytometer was viewed using a 
EVOS XL Cell Imaging Microscope System (Life Technologies: Carlsbad, CA). 
The stock was then diluted to about 1-2 million celis/mL followed by the addition 
of 5 % sterile DMSO (Sigma Aldrich: St. Louis, MO). Then 1 mL of cells were 
aliquoted into Fischer Scientific cryogenic vials and frozen at -BO°C. A freezer 
stock of cells was used after the cells grew for 25 passages. The frozen freezer 
stocks were melted and maintained as described in initial growth section above. 
Cell Treatment and CeliTiter-Glo Luminescent Cell Viability Assay. During 
the cell treatment process, cells were resuspended using the same appropriate 
media but without sodium pyruvate. Furthermore, before the cells were split for a 
new passage, the cells were counted using the hemocytometer. The appropriate 
dilutions were made with media without sodium pyruvate for plating using a bio-
one CELLSTAR 96 well, cell culture plate (Greiner: KremsmOnster, Austria) with 
70 IJL of liquid at cell concentrations ranging from 1000-10,000 cells/well. After 
overnight incubation, the cells in triplicate underwent three cell culture treatments 
using a Thermo Scientific 12 channel electronic pipette: no media replacement, 
media replacement, and wash twice with 70 IJL of DP8S then media 
replacement. One experiment involved determining the best technique to remove 
the media without removing cells by using either electronic pipette, vacuum 
pipette, or inverting the plate. Following these treatments, cells were treated with 
one type of drug: either benserazide, hydrogen peroxide, or buthionine 
sulfoximine (8S0) ranging in concentration from 244 nM - 250 IJM,- 17 nM -
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10,000 IJM, and 56 IJM - 2,000 IJM, respectively. The serial dilutions were made 
with the appropriate diluent, which maintains a constant concentration of the 
vehicle, when needed using a 12 well trough and 2 or 3 fold serial dilutions per 
well. Finally, 10 IJL of varying drug concentrations were added in each row of the 
plate using a 12 channel electronic pipette, with each column of the plate having 
the same concentration and the last column having a 0 mM concentration (media 
only) of drug added. After the plates had incubated for 72 hours, they were 
removed and 80 IJL of CeliTiter-Glo reagent (Promega: Madison, WI) was added 
to each well. The plate was shaken using a Thermo Scientific Titer Plate Shaker 
for 5 min on a speed setting of 4 then centrifuged at 250 9 for 60 seconds using a 
Thermo Scientific Sorvall ST 8. The plate was then incubated at room 
temperature. After 15 min. incubation, 80 IJL from each well was transferred to a 
white-walled 96 well plate. The results of the luminescent assay were obtained 
using a Promega GloMax Multi Detection System. The preprogrammed CeliTiter-
Glo assay parameters were used. Finally, IC50 curves were constructed using 
variable dose response curve parameters in GraphPad Software (La Jolla, CA). 
All curves were normalized by taking the CeliTiter-Glo values and dividing it by 
the top IC50 values calculated by the program. 
GSH/CeIiTiter-Glo Assays. To begin these assays, the same plating procedure 
as described in the Cell Treatment section above was conducted. However, 
when plating the cells, only 3 rows with 8 columns were plated. After 24 hours, 
the same plating treatments (Le. no media replacement, etc.) were conducted as 
12 
described in the Cell Treatment section above, preparing the cells for 
GSH/CeIiTiter-Glo assays. The GSH/CeIiTiter-Glo assays use GSH-Glo assay 
and Cell-Titer-Glo assay on the same plate but not the same wells for 
normalization of GSH levels against viable cells. The GSH-Glo assay was 
conducted per Promega protocol. To begin, all media was removed from 4 
columns and 3 rows and discarded. Then 50 ~L of Total Glutathione Lysis (TGL) 
Reagent was added to the appropriate wells containing cells and 4 (2 each) other 
wells containing no cells as a background control. The TGL reagent was made 
with the following per well composition: 1.0 ~L Luciferin-NT, 1 0.0 ~L Passive 
Lysis Buffer, 5X, and 39.0 ~L Nuclease-Free Water. After 5 min. on the plate 
shaker, 50 ~L of Luciferin Generation Reagent was added to the wells containing 
TGL or OGL Reagent with the following composition per well : 1.25 ~L 100 mM 
OTT, 3.0 ~L Glutathione-S-Transferase, and 45. 75 ~L Glutathione Reaction 
Buffer. Following a brief shake on the plate shaker and 30 min. incubation at 
room temperature, the contents of each well were transferred to a white-walled 
plate. Then 1 00 ~L of Luciferin Detection Reagent was added per well and 
incubated for 15 minutes. The results of luminescent assay were obtained using 
a Promega GloMax Multi Detection System. The CeliTiter-Glo cell viability assay 
was conducted on the other 3 rows and 4 columns worth of cells as described in 
the CeliTiter-Glo Luminescent Cell Viability Assay section above. The 
preprogrammed CeliTiter-Glo assay parameters were used. Finally, bar graphs 
were constructed by utilizing GraphPad Software containing two bars, total 
glutathione as a percent (red) and total glutathione normalized to cell number 
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(blue bar), over all three cell treatment conditions. Total glutathione as a percent 
was obtained from the GSH-Glo raw data. After correcting for background, an 
average of the no media replacement row was calculated then all numbers were 
divided by that number. Total glutathione normalized to cell number was 
calculated using normalized numbers from GSH-Glo and normalizing CeliTiter-
Glo numbers the same way as described above. Then the normalized GSH-Glo 
numbers were divided by average normalized CeliTiter-Glo numbers. Two one-
way ANOVA statistical analyses via SPSS were conducted on the red and blue 
bars to determine if changes among the cell treatments were statistically 
significant. If ANOVA received a p value less than 0.05, then Tukey's statistical 
test was conducted to determine where the difference is. 
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CHAPTER 3 
Results and Discussion: 
On November 14th , 2014 the first experiments were conducted with MDA-
MB-231 and eseroline at a cell count of 1,000 cells/well to become familiar with 
the experimental techniques of cell culture and drug treatment (results not 
known). Eseroline was initially chosen as a drug to induce cell death through 
ROS; however, after further experiments in the lab, a better ROS drug inducer 
was chosen. (1) The drug functions as a toxic metabolite of physostigmine, an 
anti-cholinesterase drug. (2) Its mechanism of action causes cell death by 
inducing lactic acid dehydrogenase (LDH) leakage, ultimately causing ATP loss. 
(2) Furthermore, it became clear from those experiments that using a pipette 
connected to a vacuum was not the best way to remove the media because there 
was cell loss based on the IG50 curve (or lack thereof). Data for IG50 curves were 
obtained by using the GeliTiter-Glo assay system. This system measures the 
number of living cells indirectly by measuring ATP, an essential energy molecule 
for living cells, using a luminescent signaling though the use of luciferase. (4) An 
optimization experiment was developed, which included plating cells at the same 
cell count and in triplicate removing the media using a pipette connected to a 
vacuum, using a 12 channel electronic pipette, and finally just inverting the plate 
on paper towel. All of these were done at the side of the well to minimize any cell 
loss. Researchers have implemented the last technique and although it makes 
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sense, the technique lends itself to contamination issues, media retention inside 
the wells, lack of analytical method, and a large mess. The results (not shown) 
indicated that the best way to remove the media was through a 12 channel 
electronic pipette, because it showed the least amount of cell loss. 
A better ROS inducer, benserazide, was selected the following semester, 
and to see a more profound effect in cell death, a cell count of 10,000 cells/well 
was used for plating. Benserazide, a drug used in Parkinson treatment, was 
shown by another colleague in the lab to induce more hydrogen peroxide, H202, 
in media than eseroline, especially media without sodium pyruvate. (1) The 
structural components of benserazide, specifically the hydroxyl groups on the 
phenyl ring, permits oxidation reactions creating ROS in medium. (3) Results of 
Benserazide triplicates from one experiment are shown in Figure 1. Results 
indicate a drop in IC50 values from both plating treatments compared to the 
control as hypothesized. The plating treatments included: no media replacement, 
media replacement, and 2 time wash with PBS following by media replacement 
resulting in 13.78 !-1M, 10.40 !-1M, and 8.45 !-1M IC50 values, respectively. The IC50 
is defined as the concentration of the inhibitor, in this case drug, which reduces 
the response by half, or in this case reduces the viable cells. These results were 
in line with the hypothesis that common cell maintenance procedures cause loss 
of essential proteins and compounds necessary for viable cell growth. We 
hypothesized that the most important loss was that of GSH, thereby causing a 
decrease in viability due to the inability to fight ROS. To corroborate these 
findings, we tried to quantify the amount of total GSH (GSH and GSSG) inside 
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the cells and the media itself after treatment. Unfortunately, the results (not 
shown) were not usable because of the cysteine found in the MEM media, which 
interfered with measuring the total GSH content in the media. Moreover, the 
results from the ICso curves were not as profound as were hypothesized. Along 
with the PI, it was decided to forgo ROS induction and use low concentrations of 
H20 2 to induce cell death. Experiments with hydrogen peroxide began on March 
6th , 2015 with a cell count of 10,000 cells/well. These results (not shown) were 
unreliable and there was not enough time to do more experiments before the 
safety cabinet was shut down for almost 5 months. Before the shutdown, one 
simple experiment was conducted using a drug called BSO. BSO was found to 
deplete cells of GSH. (5) So to see a more intense effect on cell death, we 
decided to use BSO. However, at any concentration, BSO would cause cell 
death after 24 hours, as shown in Figure 2. It was not possible to use BSO, 
because we wanted to see a more profound effect of the drug over a three-day 
period. After 96 hours, the cells were not viable at 25 IJM 8S0, and by adding 
another drug such as peroxide, the results would only show zero viable cells. 
Following the shutdown, experimental results were not obtained again 
until October 2015. During the shutdown, there was a break in the cryogenic 
freezers, leading to thawing of freezer stocks. All new cell lines were ordered. In 
September 2015, MDA-MB-231 and MDA-MB-468 were thawed and new freezer 
stocks were made. It was during this time that the PI thought it was best to see 
this hypothesized effect over two different cell lines. Cell viability experiments 
began with MDA-MB-468 at 1,000 cells/well; however, the results were not 
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credible (not shown). It was determined to run another optimization experiment 
on the cell line to decide the best cell plating count. The results (not shown) 
concluded that cell plating should be done at 5,000 cells/well for optimal cell 
viability results. From that point on, all experiments in both cell lines were 
conducted at that cell concentration. In 2 months, 4 cell viability experiments 
done in triplicate were conducted on MDA-MB-231 with hydrogen peroxide and 5 
cell viability experiments done in triplicate were conducted on MDA-MB-468 with 
hydrogen peroxide. The results were plotted on one ICsa graph for each cell line. 
In Figure 3, the results for MDA-MB-231 are shown for plating treatments: no 
media replacement, media replacement, and 2 time wash with PBS following by 
media replacement resulting in ICsa values of 47.33 !-1M, 32.59 !-1M, and 26.92 
!-1M, respectively. In Figure 4, the same results are shown but for MDA-MB-468 
cell line for plating treatments: no media replacement, media replacement, and 2 
time wash with PBS followed by media replacement resulting in ICsa values of 
71.55 !-1M, 33.90 !-1M, and 29.97 !-1M, respectively. When looking at the results 
separately we can conclude that common cell culture maintenance techniques 
lead to a decrease in cell viability after drug treatment. When comparing the two 
cell lines, it can be deduced that MDA-MB-468 is more resistant to drug ROS 
treatment throughout the control, no media replacement, treatment because of 
the increase in ICsa values from 47.33 !-1M to 71.55 !-1M. However, upon plating 
treatments, such as media replacement and wash, the cell lines result in an 
almost identical drop in ICsa values. This may further solidify the finding that 
common cell culture maintenance techniques are detrimental to cell viability. 
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To verify the hypothesis that the results from Figure 3 and 4 are not just 
from cell loss but from loss of GSH, two assays were conducted, CeliTiter-Glo 
and GSH-Glo. The GSH-Glo assay system couples the reaction of GSH and 
glutathione-S-transferase (GST) with a derivative of luciferin, luciferin-NT, to 
create a luminescent product only in the presence of GSH, thereby measuring 
the total amount of GSH in the cell. (6) To that end, we performed both assays on 
the same plate in order to see the total amount of GSH (%) normalized to the 
amount of cells present. The findings are found in Figures 5 and 6 (MDA-MB-231 
and MDA-MB-468, respectively). The red columns in Figure 5, MDA-MB-231, 
show only normalized total GSH percentage values. To determine if the 
difference between each treatment is significant, a one-way ANOVA revealed 
that there is a difference (p = 0.02). To determine where the difference lies, 
Tukey's statistical test was conducted and revealed that the difference is 
between No Media Replacement & PBS Wash and Media Replacement (p = 
0.02). This means that we do see a significant decrease in GSH values between 
those two treatments. However, further testing, as shown by the blue bars, 
shows that the GSH decrease is due to cell loss because one-way ANOVA 
reveals that there is no significant change (p > 0.05) across treatments when 
normalized to cell number. 
In Figure 6, MDA-MB-468, the red columns show only normalized total 
GSH percentage values. A one-way ANOVA revealed that there is a significant 
difference between treatments (p < 0.001). Tukey's test reveals that there is 
difference between No Media Replacement & Media Replacement (p < 0.001), 
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and No Media Replacement & PBS Wash and Media Replacement (p < 0.001) 
but there is no difference between Media Replacement & PBS Wash and Media 
Replacement (p > 0.05). This means that we do see a significant decrease in 
GSH values between those two treatments. This difference may only be due to a 
loss of cells. To account for this loss, another one-way ANOVA (p = 0.05) was 
conducted on the blue bars showing total GSH percentage normalized to cell 
number. Finally, to determine where this difference occurs, Tukey's test shows 
one difference between No Media Replacement & PBS Wash and Media 
Replacement (p = 0.04). Therefore, the loss of GSH is not due to cell loss and 
that we do see a statistical significant decrease in total GSH when we wash the 
cells. To conclude for certain that this loss is significant in this cell lines, we still 
believe that further testing needs to be done. The statistical values are too close 
to threshold, where the difference may still be due to chance. It is certain though 
that each cell line exhibits different GSH loss when exposed to common cell 
plating techniques. Finally, although we see very little evidence for loss of GSH 
causing a decrease in cell viability, more testing is needed to replicate these 
results and draw the same conclusions. 
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Effects of Benserazide on MDA-MB-231 
150 
No Media Replacement 
; 100 J t 111 11 ...... IC 50= 13.78 J,I M 
0 I .1. :1: 111 . Media Replacement CI) ...... 




PBS Wash & Media Replacement 
~ IC 50 =8.45 J,lM 0 
o I . --
-3 -2 -1 0 1 2 3 
Log 10 ([Benserazide]), IJM 
Figure 1: Data were plotted using triplicates of MDA-MB-231 at a seeding density of 10,000 cells/well from one 
experiment. The relative light units (RLU) were normalized using the top ICso values (results not shown) from each plating 
treatment resulting in a plateau at 100 % Viable Cells. The x-axis is a log scale of Benserazide concentrations used in 
drug treatment ranging from 250 IJM to 0 IJM in 11 2-fold serial dilutions. Three resulting ICso values were calculated for 
each plating treatment: No Media Replacement - 13.78 IJM (Red), Media Replacement - 10.40 IJM (Blue), and PBS 
Wash (2X) then Media Replacement (Black) - 8.45 IJM. 
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Figure 2: Data were plotted using triplicates of MDA-MB-231 at a seeding 
density of 10,000 cells/well from one experiment. The relative light units (RLU) 
obtained from the experiment were plotted against Buthionine Sulphoximine 
(BSO) concentrations used in drug treatment ranging from 2000 ~M to 0 ~M in 5 
3-fold serial dilutions. Luminescent cell viability results were obtained after 24 
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Figure 3: Data were plotted using triplicates of MDA-MB-231 at a seeding density of 5,000 cells/well from 4 experiments. 
The relative light units (RLU) were normalized using the top ICso values (results not shown) from each plating treatment 
resulting in a plateau at 100 % Viable Cells. The x-axis is a log scale of Hydrogen Peroxide concentrations used in drug 
treatment ranging from 5,000 IJM to a IJM in 11 3-fold serial dilutions. Three resulting ICso values were calculated for each 
plating treatment: No Media Replacement - 47.33 IJM (Red), Media Replacement - 32.59 IJM (Blue), and PBS Wash (2X) 











Effects of Hydrogen Peroxide on MDA-MB-468 
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Figure 4: Data were plotted using triplicates of MDA-MB-468 at a seeding density of 5,000 cells/well from 5 experiments. 
The relative light units (RLU) were normalized using the top IGso values (results not shown) from each plating treatment 
resulting in a plateau at 100 % Viable Cells. The x-axis is a log scale of Hydrogen Peroxide concentrations used in drug 
treatment ranging from 5,000 ~M to 0 ~M in 11 3-fold serial dilutions and 1 ,000 ~M to 0 ~M in 11 3-fold serial dilutions. 
Three resulting ICso values were calculated for each plating treatment: No Media Replacement - 71.55 ~M (Red), Media 
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Figure 5: To investigate the finding from Figure 3, data were plotted using 
quadruplicates of MDA-MB-231 at a seeding density of 5,000 cells/well from 3 
experiments. The total cellular glutathione percentages (Red Bars) were 
measured using GSH-Glo Assay and plotted against three plating treatments. 
Luminescent cell viability results were also obtained using the CeliTiter-Glo 
Assay. The percentage total glutathione was then normalized using cell viability 
percentages (Blue Bars). A one-way ANOVA across the red data shows that 
there is a statistical significant difference (p < 0.05). Tukey's test shows that the 
difference occurs when comparing No Media Replacement to PBS Wash and 
Media Replacement. However, no statistical significant difference is shown in the 
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Figure 6: To investigate the finding from Figure 4, data were plotted using 
quadruplicates of MDA-MB-231 at a seeding density of 5,000 cells/well from 3 
experiments. The total cellular glutathione percentages (Red Bars) were 
measured using GSH-Glo Assay and plotted against three plating treatments. 
Luminescent cell viability results were also obtained using the CeliTiter-Glo 
Assay. The percentage total glutathione was then normalized using cell viability 
percentages (Blue Bars). A one-way ANOVA across the red data shows that 
there is a statistical significant difference between the red bars (p < 0.05). 
Tukey's test shows that the difference is among all treatments when comparing 
to the control. Furthermore, a one-way ANOVA across the blue data shows that 
there is a statistical significant difference between the blue bars (p = 0.05). 
Tukey's test shows that the difference occurs when comparing No Media 
Replacement to PBS Wash and Media Replacement. 
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CHAPTER 4 
Conclusion and Future Work: 
The research done for this thesis does in fact show strong evidence that 
common cell culture and plating techniques do decrease cell viability; however, 
the mechanism is not through GSH loss and is still unknown. This evidence is 
shown by thedecrease in IGso in both cell lines as presented in Figures 3 and 4. 
In addition, Figures 5 and 6 show that the loss of GSH is due to cell loss and 
therefore, a decrease in cell viability is not due to a loss of GSH. Further 
research is needed to speculate on the cause of this decrease in cell viability. 
The two year long thesis research project had many difficulties, the 
biggest being time. To make this project better in the future, more time in the lab 
is necessary. In addition, when we began, the cell lines were not growing well, it 
is advised that fresh cell lines be purchased along with high quality serum, which 
we did almost 1.5 years in. Furthermore, knowledge and optimization are key. 
Before starting the project, having a broad and somewhat in-depth understanding 
of the experiments is helpful. Many of the optimizations we conducted would 
have saved a lot of time had we done them in the beginning. This way equipment 
and chemicals are not wasted. 
Future projects with this research are endless. For example, extending to 
more plating treatments among 10 different cell lines is a possibility. It is not 
unheard of to have 5 undergraduate students running three cell lines or having 3 
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undergraduates run 3 cell lines each. Moreover, the drugs can be changed; 
expanding into clinically tested ROS drugs or even reactive nitrogen species. In 
addition, expanding to other assays or experimental techniques that measure 
GSH may also be an option. An understanding of GSH from this perspective may 
lead to other projects such as continued research discovery on human GSH 
transporters. A grant has been developed and written for this research topic, if 
the PI would like to explore this route. 
The possibilities are endless for GSH research; however, with this 
research evidence, we urge the scientific community to develop better in vitro 
techniques that are more consistent with in vivo conditions. 
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